Meeting Coverage
Expert Perspectives
Journal Review
Podcasts & Audio
Dr. Mostaghimi discusses the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials that assessed the efficacy of deuruxolitinib in patients with alopecia areata.